[{"id":"5351b2fd-adc5-41e4-92bd-076122f48c07","acronym":"BRI-ROL-001","url":"https://clinicaltrials.gov/study/NCT03328026","created_at":"2021-01-18T16:26:04.427Z","updated_at":"2025-02-25T16:52:02.280Z","phase":"Phase 1/2","brief_title":"Combination Study of SV-BR-1-GM With Retifanlimab","source_id_and_acronym":"NCT03328026 - BRI-ROL-001","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • Bria-IMT (SV-BR-1-GM) • Intron A (interferon α-2b) • cyclophosphamide intravenous"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 36","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 11/03/2025","primary_completion_date":" 11/03/2025","study_txt":" Completion: 11/30/2028","study_completion_date":" 11/30/2028","last_update_posted":"2025-02-04"},{"id":"bd75f6cb-9c61-46b7-9c32-2458d8550dad","acronym":"BRIA-ABC","url":"https://clinicaltrials.gov/study/NCT06072612","created_at":"2023-10-10T15:12:12.246Z","updated_at":"2024-07-02T16:34:26.318Z","phase":"Phase 3","brief_title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","source_id_and_acronym":"NCT06072612 - BRIA-ABC","lead_sponsor":"BriaCell Therapeutics Corporation","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • capecitabine • cyclophosphamide • Halaven (eribulin mesylate) • Zynyz (retifanlimab-dlwr) • Bria-IMT (SV-BR-1-GM)"],"overall_status":"Recruiting","enrollment":" Enrollment 404","initiation":"Initiation: 12/05/2023","start_date":" 12/05/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-13"},{"id":"56840cd1-de4a-4f57-9498-f5727132e914","acronym":"","url":"https://clinicaltrials.gov/study/NCT04418219","created_at":"2021-01-18T21:17:41.922Z","updated_at":"2024-07-02T16:36:29.480Z","phase":"Phase 1/2","brief_title":"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer","source_id_and_acronym":"NCT04418219","lead_sponsor":"Thomas Jefferson University","biomarkers":" HER-2 • PD-L1 • ER • PGR • PD-L2 • HLA-B • PRAME • HLA-C","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • ER positive + PGR positive • PGR positive • PGR negative • HLA-A*24","tags":["HER-2 • PD-L1 • ER • PGR • PD-L2 • HLA-B • PRAME • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • ER positive + PGR positive • PGR positive • PGR negative • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Bria-IMT (SV-BR-1-GM) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2021-06-07"}]